Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11134387 | 1.00 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL6539020 | 1.00 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL11125923 | 0.81 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL10817869 | 0.79 | NPSR1 (0.47) | HCAR2 | |
| SCHEMBL10817860 | 0.79 | NPSR1 (0.47) | HCAR2 | |
| SCHEMBL831789 | 0.79 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL10967253 | 0.79 | SLC1A3 (0.33) | HCAR2 | |
| SCHEMBL10967248 | 0.79 | SLC1A3 (0.33) | HCAR2 | |
| SCHEMBL831788 | 0.79 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL8069973 | 0.76 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051345-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2025-02-13 | — | — | US | disclosed |
| EP-4448533-A1 | <SUP2/>? <SUB2/>?V?PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CA1.2 ACTIVATORS | Novartis AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118510782-A | As CaV1.2 Pyridine-3-carboxylic acid ester Compounds of activators | 诺华股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023111799-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| WO-2004022540-A2 | PYRIDAZINONE AND PYRIDONE DERIVATIVES AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-18 | — | — | WO | disclosed |
| EP-0177965-B1 | NOVEL OXA- AND THIADIAZOLYL DERIVATIVES AND THEIR USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-03-21 | — | — | EP | disclosed |
| US-4857515-A | Certain antihypertensive 1,4-dihydro-6-methyl-5-phosphonic acid-4-aryl-3-carboxylic acid-2-cyano diesters | NIPPON SHINYAKU CO., LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0063747-B1 | 2-SUBSTITUTED OR UNSUBSTITUTED AMINOCARBONYLOXYALKYL-1,4-DIHYDROPYRIDINES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-12-09 | — | — | EP | disclosed |
| US-4705786-A | Novel oxadiazolyl-1,4-dihydropyridines useful as antihypertensive agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-10 | — | — | US | disclosed |
| EP-0177965-A2 | Novel oxa- and thiadiazolyl derivatives and their use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| US-4579859-A | HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-01 | — | — | US | disclosed |
| EP-0174131-A2 | Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
| EP-0127150-A2 | 2,6-Disubstituted-1,4-dihydropyridine derivative, process for the preparation of the same and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-05 | — | — | EP | disclosed |
| US-4404378-A | HYPOTENSIVE AGENTS; VASODILATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1983-09-13 | — | — | US | disclosed |
| EP-0063747-A1 | 2-Substituted or unsubstituted aminocarbonyloxyalkyl-1,4-dihydropyridines | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1982-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | ADORA1, ADORA2A, P2RX5 | HCAR2 1877/4885KEAP1 823/4885NFE2L2 2052/4885 |
| US-20250051345-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | CACNA1D, CACNA1S, CACNA1I | HCAR2 1130/4885KEAP1 2913/4885NFE2L2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.